Treatment with pegylated interferon ( peg-IFN ) alfa-2a ( 40KD ) results in hepatitis B `` e '' antigen ( HBeAg ) seroconversion 6 months after treatment in up to 36 % of HBeAg-positive chronic hepatitis B patients .